Global Gout Therapeutics Market Data 2024, Forecast To 2033
8 Mar, 2024
The gout therapeutics market has experienced rapid growth, expanding from $2.54 billion in 2023 to $2.86 billion in 2024, with a CAGR of 12.7%. This growth is attributed to factors such as increased prevalence of gout and lifestyle changes, alongside developments in treatment options. Looking ahead, the market is projected to continue its rapid growth, reaching $4.41 billion by 2028, with a CAGR of 11.5%. Factors driving this growth include rising healthcare expenditure, advancements in drug delivery systems, and government initiatives for chronic disease management. Additionally, trends such as innovative drug development and personalized medicine approaches are expected to shape the market, alongside the integration of telehealth services for gout management and research into urate-lowering therapies.
Global Gout Therapeutics Market Key Driver
The rising incidence of gout drives the growth of the gout therapeutics market. Gout, an inflammatory arthritis condition, causes joint pain and swelling, with therapeutic interventions aimed at alleviating symptoms. The UK's National Health Service recorded a 20% increase in new gout cases between 2021 and 2022 in British hospitals, indicating a growing demand for gout therapeutics. Therefore, the escalating occurrence of gout stimulates the expansion of the gout therapeutics market.
Get A Free Sample Of The Global Gout Therapeutics Market ReportGlobal Gout Therapeutics Market Segments
The gout therapeutics market covered in this report is segmented –
1) Type:Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroid, Diuretics
2) Treatment:Xanthine Oxidase Inhibitor, Uricosuria Medication
3) Disease Condition:Acute, Chronic
4) End-Users:Hospitals, Specialty Clinics, Other End Users
By Geography: The countries covered in the gout therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the gout therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gout therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Gout Therapeutics Industry Players
AbbVie Inc.; Sanofi-Aventis; AstraZeneca plc; LG Chem Ltd.; GlaxoSmithKline Plc; Takeda Pharmaceuticals Co. Ltd.; Boehringer Ingelheim International GmbH; Regeneron Pharmaceuticals Inc.; Astellas Pharma Inc.; Sandoz; Eisai Co. Ltd.; Horizon Pharma Plc; Jiangsu HengRui Medicine Co. Ltd.; Hikma Pharmaceuticals plc; Swedish Orphan Biovitrum AB; JW Pharmaceutical Corp; Lannett Company Inc; BioCryst Pharmaceuticals Inc.; Selecta Biosciences Inc.; Rigel Pharmaceuticals Inc.; Avion Pharmaceuticals LLC; Protalix BioTherapeutics Inc.; Teijin Pharma Limited; Romeg Therapeutics LLC.; CymaBay Therapeutics Inc.; GeneScience Pharmaceuticals Co. Ltd.; Shanton Pharma
Get The Full Global Gout Therapeutics Market Report
Gout Therapeutics Market Overview
Gout therapeutics refers to medication that exerts therapeutic effects in treating the disease condition known as gout, or inflammatory arthritis, which causes pain and swelling in joints. Gout therapeutics treat and relieve pain, swelling, and tenderness in joints.